Oxytocin acetate: what the published research shows

Oxytocin acetate is the acetate salt form of oxytocin, a nine-amino-acid cyclic nonapeptide (Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, with a disulfide bridge between the two cysteine residues) with a molecular weight of approximately 1007.19 g/mol as the free peptide. Synonyms include oxytocin diacetate and oxytocin acetate salt. It is classified as a posterior pituitary hormone and a member of the oxytocin/vasopressin peptide family. The research literature centres on the oxytocin receptor (OXTR), a G-protein-coupled receptor that signals through Gq/11 to mobilise intracellular calcium, and on the structurally related vasopressin receptors (V1a, V1b, V2), which oxytocin can cross-react with at higher concentrations.

Oxytocin acetate is supplied as a lyophilised powder for laboratory research use. The studies below span veterinary reproductive physiology, human neuroendocrine challenge paradigms, obstetric anaesthesia and preterm labour pharmacology. Where a finding comes from an animal model or an in vitro system, this is stated explicitly.

Research Studies

Oxytocin acetate and uterine involution in dairy cows

A randomised controlled trial in 80 dairy cows compared three substances with ecbolic activity — oxytocin, prostaglandin F2α and scopolamine — for their effect on uterine involution and resumption of ovarian activity after calving [3]. Cows were assigned to four groups of 20: saline control; 150 µg/head d-cloprostenol; 50 IU/head oxytocin acetate; or 40 mg scopolamine butylbromide, all administered within 24 hours of calving. Blood samples were collected to evaluate hydroxyproline as a marker of collagen turnover. This is an animal study; findings in cattle do not translate directly to human reproductive physiology.

Oxytocin and endogenous release in paediatric pituitary disease

An open-label interventional pilot trial is recruiting 10 youth with arginine-vasopressin deficiency (AVP-D) and 10 paediatric patients with pituitary disease matched for age, sex and BMI from paediatric endocrinology and neuroendocrinology clinics and the community [1]. The study tests the hypothesis that oral estrogen/progestin will stimulate endogenous oxytocin release in control subjects. Eligible participants receive two tablets in a single administration containing a total of 1 mg norethindrone acetate and 70 µg ethinyl estradiol. Blood and saliva are sampled at baseline and approximately 24 hours after study drug administration, alongside neuropsychological assessment of anxiety, mood and emotion regulation. This trial is ongoing; no results are reported in the registry entry.

Oxytocin response to estrogen-progestin in adults with pituitary disease

A separate open-label pilot study is characterising the oxytocin response to a single dose of oral estrogen-progestin in patients with arginine-vasopressin deficiency compared with healthy controls [2]. The stated hypotheses are that salivary and blood oxytocin responses to estrogen-progestin will be lower in AVP-D than in healthy controls, and that lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression and social-emotional difficulties, as well as lower quality of life. This study is ongoing; the registry entry does not report outcomes.

Oxytocin receptor antagonism and preterm labour

A randomised, double-blind, double-dummy study compared retosiban with atosiban in women with spontaneous preterm labour [7]. Atosiban is described in the registry entry as a mixed oxytocin-vasopressin antagonist indicated for short-term use to delay imminent preterm birth in women between 24^0/7 and 33^6/7 weeks' gestation. The primary objective was to demonstrate superiority of retosiban over atosiban in prolonging pregnancy, based on the hypothesis that prolonging time to delivery in the absence of harm may benefit the newborn, particularly at early gestational ages. This is a human clinical trial; the registry entry does not report results.

Oxytocin and cardiac output during caesarean delivery

A clinical study is measuring cardiac output in healthy parturients undergoing caesarean delivery under spinal anaesthesia [4]. The registry entry does not specify an oxytocin intervention, but oxytocin is routinely administered in this setting as a uterotonic, and the study population is relevant to research on oxytocin's cardiovascular effects in obstetric anaesthesia. This is a human observational study; no results are reported in the registry entry.

Oxytocin and fluid assessment in preeclampsia

A study is using ultrasonography for fluid assessment in parturients with preeclampsia undergoing caesarean section [5]. Preeclampsia is described as a multifocal syndrome reported in 2–8% of pregnancies, diagnosed in the second half of pregnancy by two separate measurements of systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg in the same arm and proteinuria >300 mg in 24-hour urine collection. The risk for serious complications such as pulmonary oedema, cerebrovascular accidents, coagulopathy and haemorrhage is 10- to 30-fold higher among parturients with severe preeclampsia. Severe preeclampsia is defined by one or more clinical features including severe hypertension (systolic arterial pressure ≥160 mmHg and/or diastolic arterial pressure ≥110 mmHg on more than one occasion). This study does not directly investigate oxytocin but is included here because oxytocin is commonly used in this population for uterotonic prophylaxis, and the registry entry provides context for research on oxytocin's safety profile in hypertensive disorders of pregnancy.

Oxytocin and colloid versus crystalloid resuscitation in preeclampsia

A study is comparing combined colloids and crystalloids versus crystalloids alone in women with preeclampsia undergoing elective caesarean delivery under spinal anaesthesia [6]. As with the previous entry, this study does not directly investigate oxytocin, but the population and setting are relevant to research on oxytocin's haemodynamic effects in preeclampsia. The registry entry does not report results.

Oxytocin agonist combined with rTMS in a mouse model of postpartum depression

A study in mice investigated the combination of repetitive transcranial magnetic stimulation (rTMS) and an oxytocin agonist for depression-like behaviour after postpartum depression [8]. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) categorises postpartum depression as a subtype of major depressive disorder with peripartum onset, generally arising within the initial trimester following delivery. This is an animal study; the findings are not directly translatable to human postpartum depression, and the registry entry does not provide quantitative results.

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research only. We do not provide dosing or medical guidance, and nothing here should be taken as a recommendation for human use. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Identifying Oxytocin Deficiency in Pediatric Patients With Pituitary Disease — ClinicalTrials.gov
• [2] Identifying Oxytocin Deficiency in Adults With Pituitary Disease — ClinicalTrials.gov
• [3] Oxytocin, prostaglandin F2α, and scopolamine for uterine involution of dairy cows — Europe PMC
• [4] Changes in Cardiac Output During Cesarean Delivery Under Spinal Anesthesia — ClinicalTrials.gov
• [5] Ultrasonography for Fluid Assessment in Parturients With Preeclampsia Undergoing Cesarean Section — ClinicalTrials.gov
• [6] Combined Colloids And Crystalloids Versus Crystalloids in Women With Preeclampsia Undergoing Cesarean Delivery — ClinicalTrials.gov
• [7] A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour — ClinicalTrials.gov
• [8] Combination of rTMS and oxytocin agonist attenuate depression-like behavior after postpartum depression in mice — PubMed